--- title: "HCW Biologics (HCWB) news: reverse split and going concern" url: "https://aibio.space/companies/hcw-biologics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "HCWB reverse split, going concern, offering and lawsuit news: HCW Biologics regains Nasdaq bid price compliance, faces monitor until June 17, 2027." --- HCWB HCW Biologics Inc. NASDAQ · United States # HCW Biologics (HCWB) news HCWB reverse split, going concern and offering news Legal · 2026-08-14 ## [HCW Biologics faces December jury trial in Florida mechanics lien foreclosure case](https://aibio.space/news/hcw-biologics-faces-december-jury-trial-florida-mechanics-lien/) BE&K Building Group sued HCW Biologics, Cogent Bank and subcontractors in Broward County over unpaid renovation invoices. Fisk Electric's suit was consolidated, and Cogent Bank has demanded the liens be cleared. ## Latest HCW Biologics news 1. 2026-07-29 Financings [HCW Biologics prices $1.6 million private placement with insiders and a stockholder](https://aibio.space/news/hcw-biologics-prices-1-6-million-private-placement-insiders/) The company agreed to sell 618,682 units at $2.585 per unit, including shares to its founder, chairman and an officer, and the common warrants need stockholder approval. 2. 2026-06-30 Listings [HCW Biologics regains Nasdaq bid price compliance, faces monitor until June 17, 2027](https://aibio.space/news/hcw-biologics-regains-nasdaq-bid-price-compliance-faces-monitor-until/) A Nasdaq Hearings Panel found HCW Biologics (Nasdaq: HCWB) back in compliance with the minimum bid price rule. The company faces a mandatory panel monitor and will effect a one-for-six reverse stock split on June 30, 2026. 3. 2026-05-21 Financings [HCW Biologics prices about $4.0 million private placement with E.F. Hutton as agent](https://aibio.space/news/hcw-biologics-prices-about-4-0-million-private-placement-e-f-hutton/) The company priced 2,846,975 units at $1.405 each to a group of healthcare investors, and the warrants are exercisable at $1.28 per share. 4. 2026-05-14 Company Updates [HCW Biologics reports first-quarter 2026 net income on Trimmune license](https://aibio.space/news/hcw-biologics-reports-first-quarter-2026-net-income-trimmune-license/) The company reported $6.5 million in revenue and net income of $3.5 million for the quarter ended March 31, 2026, and it still states substantial doubt about going concern. 5. 2025-10-16 Listings [HCW Biologics wins Nasdaq panel extension to meet equity rule by December 31, 2025](https://aibio.space/news/hcw-biologics-wins-nasdaq-panel-extension-meet-equity-rule-december-31/) A Nasdaq Hearings Panel granted HCW Biologics (Nasdaq: HCWB) continued listing on October 13, 2025. The company must show compliance with the Equity Rule by December 31, 2025 and with all other rules by February 16, 2026. 6. 2025-08-19 Listings [HCW Biologics faces Nasdaq suspension over equity rule and plans to request a hearing](https://aibio.space/news/hcw-biologics-faces-nasdaq-suspension-equity-rule-plans-request/) Nasdaq says HCW Biologics was out of compliance with its equity rule on June 30, 2025. The shares would be suspended on August 28 unless the company asks for a hearing by August 26. 7. 2025-08-15 Distress [HCW Biologics delays quarterly report for period ended June 30, 2025](https://aibio.space/news/hcw-biologics-delays-quarterly-report-period-ended-june-30-2025/) HCW Biologics says it needs more time to finish its June quarter 10-Q and expects to file within the five-day grace period. The notice gives no revenue, loss or cash figures. 8. 2025-05-15 Financings [HCW Biologics closes $5.0 million offering of 671,140 units at $7.45](https://aibio.space/news/hcw-biologics-closes-5-0-million-offering-671-140-units-7-45/) Each unit carries two warrants exercisable at $7.45, and Maxim Group was sole placement agent. The prospectus carries going-concern doubt and a Nasdaq compliance warning. ## HCW Biologics at a glance - **Ticker**: HCWB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $741,324 ### Related companies - [Wave Life Sciences](https://aibio.space/companies/wave-life-sciences/) NASDAQ: WVE - [Amarantus Bioscience Holdings](https://aibio.space/companies/amarantus-bioscience/) OTC: AMBS - [Replimune Group](https://aibio.space/companies/replimune/) NASDAQ: REPL - [Rallybio](https://aibio.space/companies/rallybio/) NASDAQ: RLYB - [Lunai Bioworks](https://aibio.space/companies/lunai-bioworks/) NASDAQ: LNAI - [LeonaBio](https://aibio.space/companies/leonabio/) NASDAQ: LONA - [Whitehawk Therapeutics](https://aibio.space/companies/whitehawk-therapeutics/) NASDAQ: WHWK - [Nkarta](https://aibio.space/companies/nkarta/) NASDAQ: NKTX ### Also on NASDAQ - [LivaNova](https://aibio.space/companies/livanova/) LIVN - [Alpha Tau Medical](https://aibio.space/companies/alpha-tau-medical/) DRTS - [TELA Bio](https://aibio.space/companies/tela-bio/) TELA - [Q32 Bio](https://aibio.space/companies/q32-bio/) QTTB - [Mineralys Therapeutics](https://aibio.space/companies/mineralys-therapeutics/) MLYS - [Lakewood-Amedex Biotherapeutics](https://aibio.space/companies/lakewood-amedex-biotherapeutics/) LABT ## What HCW Biologics does HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for diseases promoted by chronic inflammation, including autoimmune disorders, other proinflammatory diseases, cancer and senescence-associated dysplasia. It builds these molecules on two platforms: TOBI, which uses a Tissue Factor scaffold, and TRBC, which uses a T-cell Receptor beta chain constant region scaffold. Its lead clinical candidate, HCW9302, is an injectable IL-2 fusion protein that activates regulatory T cells. The first patient was dosed on November 17, 2025, in a first-in-human trial in alopecia areata. Beijing Trimmune Biotech Co., Ltd. has an option to license HCW9302 rights for China. HCW11-006 is being developed with Trimmune, which holds exclusive worldwide rights for in vivo applications of that compound. The company has begun commercializing two commercial-ready reagents, HCW9206 and HCW9201, for producing CAR-therapies and natural killer cell-based therapies. A Science Advances publication on March 13, 2026, reported company data on HCW9206 in CAR-T cell manufacturing. | Product or program | What it is | Stage | |---|---|---| | HCW9302 | Injectable IL-2 fusion protein that activates regulatory T cells, in alopecia areata | clinical-stage | | HCW9206 | Fusion protein reagent for producing CAR-therapies | commercial-ready | | HCW9201 | Fusion protein reagent for producing natural killer cell-based therapies | commercial-ready | | HCW11-018b | Tetra-valent T-cell engager designed to treat solid tumors | preclinical | | HCW11-006 | Multi-functional immune cell stimulator developed with Trimmune | preclinical | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/hcwb-20251231.htm). ## HCW Biologics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$5.4 million](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/) | [$6.4 million](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/) | | Net income (loss) | [-$8.0 million](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/) | [-$30.0 million](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/) | | Cash from operations | [-$13.4 million](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/) | [-$14.2 million](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/) | | Cash and equivalents | [$2.0 million](https://www.sec.gov/Archives/edgar/data/1828673/000149315226038246/) | [$4.7 million](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/) | | Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/) | [$0](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $741,324, plus short-term investments of $0, $741,324 in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about HCW Biologics Did HCW Biologics do a reverse stock split? Our latest story on this, dated Jun 30, 2026: "HCW Biologics regains Nasdaq bid price compliance, faces monitor until June 17, 2027". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/hcw-biologics-regains-nasdaq-bid-price-compliance-faces-monitor-until/). Has HCW Biologics issued a going-concern warning? Our latest story on this, dated May 14, 2026: "HCW Biologics reports first-quarter 2026 net income on Trimmune license". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/hcw-biologics-reports-first-quarter-2026-net-income-trimmune-license/). Has HCW Biologics raised money recently? Our latest story on this, dated Jul 29, 2026: "HCW Biologics prices $1.6 million private placement with insiders and a stockholder". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/hcw-biologics-prices-1-6-million-private-placement-insiders/). Is HCW Biologics involved in a lawsuit? Our latest story on this, dated Aug 14, 2026: "HCW Biologics faces December jury trial in Florida mechanics lien foreclosure case". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/hcw-biologics-faces-december-jury-trial-florida-mechanics-lien/). What is the ticker symbol of HCW Biologics? HCW Biologics Inc. trades under the ticker HCWB on NASDAQ. Where is HCW Biologics listed? HCW Biologics Inc. is listed on NASDAQ. What is the SEC CIK of HCW Biologics? The SEC Central Index Key (CIK) for HCW Biologics Inc. is 1828673. Its filings are on SEC EDGAR. How many shares does HCW Biologics have outstanding? 1,836,324 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is HCW Biologics listed under? Our directory records HCW Biologics Inc. under United States. What does HCW Biologics do? Our directory classifies HCW Biologics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of HCW Biologics? The ISIN recorded for HCW Biologics Inc. is US40423R3030. Does aibio.space cover HCW Biologics? aibio.space lists HCW Biologics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is HCW Biologics incorporated? SEC records list its state or country of incorporation as DE. What does HCW Biologics develop? HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for diseases promoted by chronic inflammation, including autoimmune disorders, other proinflammatory diseases, cancer and senescence-associated dysplasia. It builds these molecules on two platforms: TOBI, which uses a Tissue Factor scaffold, and TRBC, which uses a T-cell Receptor beta chain constant region scaffold. What is HCW9302 from HCW Biologics? HCW9302: Injectable IL-2 fusion protein that activates regulatory T cells, in alopecia areata Stage: clinical-stage. ## Investor discussion: HCW Biologics Members talk about HCW Biologics (HCWB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at HCW Biologics, newest first. Each line links the filing it comes from. 1. 2026-08-14 Legal Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000149315226038240/form8-k.htm) 2. 2026-06-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000149315226031204/ex99-1.htm) 3. 2026-06-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000149315226030236/ex99-1.htm) 4. 2026-06-15 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000149315226028699/form8-k.htm) 5. 2026-06-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000149315226026529/form8-k.htm) 6. 2026-05-27 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000149315226025336/ex99-1.htm) 7. 2026-04-28 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1828673/000149315226019409/formdef14a.htm) 8. 2026-04-17 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1828673/000149315226017894/formpre14a.htm) 9. 2026-03-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000119312526084291/hcwb-ex99_1.htm) 10. 2025-12-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000119312525338026/hcwb-20251230.htm) 11. 2025-10-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000119312525240890/hcwb-20251013.htm) 12. 2025-08-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000095017025110174/hcwb-20250819.htm) 13. 2025-08-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1828673/000119312525181394/d29578dnt10q.htm) 14. 2025-06-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000095017025090183/hcwb-ex99_1.htm) 15. 2025-06-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000095017025082005/hcwb-ex99_1.htm) 16. 2025-05-15 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000095017025072700/hcwb-ex99_1.htm) 17. 2025-04-01 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000095017025048586/hcwb-20250401.htm) 18. 2025-04-01 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000095017025048619/hcwb-ex99_1.htm) 19. 2025-03-28 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1828673/000095017025046724/hcwb-20241231.htm) 20. 2025-03-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000095017025034169/hcwb-ex99_1.htm) 21. 2025-02-21 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1828673/000119312525032115/d930383ddef14a.htm) 22. 2025-02-11 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1828673/000119312525024372/d930383dpre14a.htm) 23. 2025-02-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000095017025016390/hcwb-20250205.htm) 24. 2024-12-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000095017024139288/hcwb-ex99_1.htm) 25. 2024-11-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1828673/000095017024129357/hcwb-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:HCWB on TradingView](https://www.tradingview.com/symbols/NASDAQ-HCWB/). ## SEC filings and registration - **SEC name**: HCW Biologics Inc. - **CIK**: 1828673 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: HCWB (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 2929 N COMMERCE PKWY, MIRAMAR, FL, 33025 - **Phone**: 954-842-2024 - **Shares outstanding**: 1,836,324 as of 2026-08-12 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [S-1](https://www.sec.gov/Archives/edgar/data/1828673/000149315226045532/forms-1.htm) filed 2026-10-02 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1828673/000149315226045289/formdef14a.htm) filed 2026-10-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1828673/000149315226044078/form8-k.htm) filed 2026-09-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1828673/000149315226042009/form8-k.htm) filed 2026-09-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1828673/000149315226041716/form8-k.htm) filed 2026-09-08 - [S-1](https://www.sec.gov/Archives/edgar/data/1828673/000149315226039452/forms-1.htm) filed 2026-08-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1828673/000149315226038262/form10-q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1828673/000149315226038258/form8-k.htm) filed 2026-08-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001828673), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details HCW Biologics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker HCWB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: HCW Biologics Inc. - **Ticker**: HCWB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US40423R3030 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-HCWB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/hcw-biologics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "HCW Biologics (HCWB) news: reverse split and going concern", 2026-10-31, https://aibio.space/companies/hcw-biologics/